


In the Claims:

Please amend claims 58-60 as follows:

58. (Amended) A compound of the formula




wherein W is H, -OCF₃, -O-Et, F, CH₃, -OCH₃, -SO₂-Me, NH₂, -NH-C(O)-Me, -NH-CH₂-phenyl, -NH-S(O)₂-2-thienyl, -NH-S(O)₂-(3,5-dimethylisoxazol-4-yl), -NH-S(O)₂-Me, -NH-S(O)₂-CH₂-phenyl, -NH-C(O)-O-CH₂-CCl₃, -NH-C(O)-O-CH₂-Ph, -NH-C(O)-O-Me or NO₂;


R¹ is H, F or -CH₂-S(O)₂-phenyl; and

R² is H, 4-Cl, 4-methyl, 5-methyl, 5-Cl, 5-F or 5-OCH₃


provided that the compound is not



or




59. (Amended) A method of using a compound of formula (IB)



(IB)

or a pharmaceutically acceptable salt thereof, wherein,

Q is H or represents a bond which is taken together with X¹ and the two nitrogen atoms to which Q and X¹ are attached and the C=Y group to which the two nitrogen atoms are attached to form




Q¹ is (C₁-C₆) alkyl;

Y is O or S;

W is H, Cl, Br, I, NO₂, CN, SCN, OCF₃, -X_q-(C(R¹⁰)₂)_a-Y¹_q-(C(R¹⁰)₂)_a-Z¹_q, or an optionally substituted group selected from the group consisting of alkyl, alkenyl, alkynyl, heterocyclyl-alkenyl, and heterocyclyl-alkynyl;

Y¹ and X are each independently selected from the group consisting of phenyl, heterocyclyl, NR¹⁰, O, S, SO, SO₂, CF₂, CFR, C=O, (C=O)NR¹⁰, SONR¹⁰, SO₂NR¹⁰(C=O), NR¹⁰SO,



q for each occurrence is independently 0 or 1;

a for each occurrence is independently 0 or an integer from 1 to 5;


R^{10} for each occurrence is independently selected from the group consisting of H, optionally substituted aryl, optionally substituted heterocyclyl and an optionally substituted alkyl group optionally substituted with one or more of the following: a C_{1-6} alkyl group optionally substituted by one or more hydroxy, halo or optionally substituted amino; a C_{1-6} alkoxy group optionally substituted by one or more hydroxy, halo or optionally substituted amino; hydroxy; halo; or optionally substituted amino;

Z^1 is H, optionally substituted alkyl, optionally substituted aryl or optionally substituted heterocyclyl;

X^1 is hydrogen, alkyl, hydroxyalkyl or represents a bond which is taken together with R^3 as described below or represents a bond which is taken together with Q as described above;

R^1 and R^2 are each independently hydrogen, halogen, hydroxy, nitro, cyano, COOH , COOX^3 , SX^3 , SO_2X^3 , SOX^3 , $\text{C}(\text{O})\text{X}^3$, $\text{NHC}(\text{O})\text{X}^3$, $\text{C}(\text{O})\text{NHX}^3$, NHSO_2X^3 or selected from an optionally substituted group consisting of alkyl, alkenyl, alkynyl, alkoxy, amino, NHX^3 , NX^3X^3 , alkylamino, arylamino, heterocyclylamino, alkylthio, alkylsulfonato, aryl, aryloxy, arylalkyl, arylalkenyl, arylalkynyl, arylalkyloxy, heterocyclyl, heterocyclcyloxy, heterocyclcylyl-alkyl, heterocyclcylyl-alkenyl, heterocyclcylyl-alkynyl, heterocyclcylyl-alkoxy, heterocyclcylylthio, heterocyclcylsulfenyl, heterocyclcylsulfonfyl, cycloalkyl, $-(\text{CH}_2)_m-(\text{CHX}^2)\text{CN}$, $-(\text{CH}_2)_m-(\text{CHX}^2)\text{COOH}$, $-(\text{CH}_2)_m-(\text{CHX}^2)\text{COOX}^3$, $-(\text{CH}_2)_m-(\text{CHX}^2)\text{SO}_2\text{X}^3$, $-(\text{CH}_2)_m-(\text{CHX}^2)\text{C}(\text{O})\text{X}^3$,

*Al
cont.*



where m is 0 to 4;

X^2 for each occurrence is independently H or an optionally substituted moiety selected from the group consisting of alkyl, alkenyl, alkynyl, carbonyl, $S(O)_p$ alkyl, $S(O)_p$ aryl, $S(O)_p$ heterocyclyl, amino, alkoxy, alkylthio, arylthio, perhaloalkyl, aryl, aryloxy, arylalkyl, arylalkyloxy, heterocyclyl and heterocyclyl-alkyl;


p is 0, 1 or 2;

X^3 for each occurrence is independently H or an optionally substituted moiety selected from the group consisting of mono- or di-alkylamino, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl and heterocyclyl-alkyl;

or when R^1 is in the 7-position of the benzothiazole ring, R^1 and W can be taken together with the carbon atoms to which they are attached to form an optionally substituted 5- or 6-membered heterocyclyl ring;

R^3 is hydrogen, or an optionally substituted moiety selected from the group consisting of carbonyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclyl-alkyl, heterocyclyl-heterocyclyl, heterocyclyl-cycloalkyl, amino, alkylamino, arylamino, alkoxy, thioalkoxy and acyl;

or R^3 and X^1 are taken together with the nitrogen atom to which they are attached to form



where Z for each occurrence is independently selected from the group consisting of oxo, or an optionally substituted moiety selected from the group consisting of $-C(O)(C_1-C_6)$ alkyl, $-C(O)$ aryl, $-C(O)N(C_1-C_6)$ alkyl, $-C(O)N$ -aryl, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, amino, mono- or di- (C_1-C_6) alkylamino, $-COO(C_1-C_6)$ alkyl, pyridyl, phenyl, phenyl (C_1-C_6) alkyl and phenyl (C_1-C_6) alkenyl;

where each of the optionally substituted moieties described hereinabove is optionally substituted by one or more substituents each independently selected from the group consisting of oxo, amino, nitro, mono- or bi- (C_1-C_6) alkylamino, hydroxy, nitrile, chloro, fluoro, bromo, iodo, CF_3 , (C_1-C_6) alkyl, $-C(O)(C_1-C_6)$ alkyl, $-COOH$, $-COO(C_1-C_6)$ alkyl,


-S-(C₁-C₆)alkyl, -S-aryl, (C₁-C₆)alkoxy, -SO₂NH₂, phenyl, phenyl(C₁-C₆)alkyl, -O-(C₁-C₆)alkyl-OH, -O-(C₁-C₆)alkyl-O-(C₁-C₆)alkyl, -O-(C₂-C₆)alkyl-N-((C₁-C₆)alkyl)_n, -N-(C₁-C₆)alkyl-OH, -N-(C₁-C₆)alkyl-O-(C₁-C₆)alkyl, -C(O)NH₂, -C(O)N((C₁-C₆)alkyl)_n, -S(O)_n(C₁-C₆)alkyl, -S(O)_naryl, -S(O)_nheterocyclyl, and heterocyclyl, where the alkyl groups mentioned herein optionally have one or more unsaturated bonds in the alkyl portion;

n is 0, 1 or 2;

as a replacement therapy for anti-inflammatory glucocorticosteroid therapy in a patient undergoing anti-inflammatory glucocorticosteroid therapy comprising the steps of replacing a glucocorticosteroid with a compound of formula (IB) or a pharmaceutically acceptable salt thereof and systemically administering the compound of formula (IB) or a pharmaceutically acceptable salt thereof.

60. (Amended) A method of using a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein,

Q is H or represents a bond which is taken together with X¹ and the two nitrogen atoms to which Q and X¹ are attached and the C=Y group to which the two nitrogen atoms are attached to form




Q¹ is (C₁-C₆) alkyl;

Y is O or S;

W is H, Cl, Br, I, NO₂, CN, SCN, OCF₃, -X_q-(C(R¹⁰)₂)_a-Y¹_q-(C(R¹⁰)₂)_a-Z¹_q, or an optionally substituted group selected from the group consisting of alkyl, alkenyl, alkynyl, heterocyclyl-alkenyl, and heterocyclyl-alkynyl;

Y^1 and X are each independently selected from the group consisting of phenyl, heterocyclyl, NR^{10} , O, S, SO, SO_2 , CF_2 , CFR, C=O, $(C=O)NR^{10}$, $SONR^{10}$, $SO_2NR^{10}(C=O)$, $NR^{10}SO$,



q for each occurrence is independently 0 or 1;

a for each occurrence is independently 0 or an integer from 1 to 5;

R^{10} for each occurrence is independently selected from the group consisting of H, optionally substituted aryl, optionally substituted heterocyclyl and an optionally substituted alkyl group optionally substituted with one or more of the following: a C_{1-6} alkyl group optionally substituted by one or more hydroxy, halo or optionally substituted amino; a C_{1-6} alkoxy group optionally substituted by one or more hydroxy, halo or optionally substituted amino; hydroxy; halo; or optionally substituted amino;

Z^1 is H, optionally substituted alkyl, optionally substituted aryl or optionally substituted heterocyclyl;

X^1 is hydrogen, alkyl, hydroxyalkyl or represents a bond which is taken together with R^3 as described below or represents a bond which is taken together with Q as described above;

R^1 and R^2 are each independently hydrogen, halogen, hydroxy, nitro, cyano, $COOH$, $COOX^3$, SX^3 , SO_2X^3 , SOX^3 , $C(O)X^3$, $NHC(O)X^3$, $C(O)NHX^3$, $NHSO_2X^3$ or selected from an optionally substituted group consisting of alkyl, alkenyl, alkynyl, alkoxy, amino, NHX^3 , NX^3X^3 , alkylamino, arylamino, heterocyclylamino, alkylthio, alkylsulfonato, aryl, aryloxy, arylalkyl,

arylalkenyl, arylalkynyl, arylalkyloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-alkyl, heterocyclyl-alkenyl, heterocyclyl-alkynyl, heterocyclyl-alkoxy, heterocyclylthio, heterocyclisulfinyl, heterocyclisulfonyl, cycloalkyl, $-(CH_2)_m-(CHX^2)CN$, $-(CH_2)_m-(CHX^2)COOH$, $-(CH_2)_m-(CHX^2)COOX^3$, $-(CH_2)_m-(CHX^2)SO_2X^3$, $-(CH_2)_m-(CHX^2)C(O)X^3$, $-(CH_2)_m-(CHX^2)C(O)NHX^3$ and $-(CH_2)_m-(CHX^2)NHSO_2X^3$;

where m is 0 to 4;

X^2 for each occurrence is independently H or an optionally substituted moiety selected from the group consisting of alkyl, alkenyl, alkynyl, carbonyl, $S(O)_p$ alkyl, $S(O)_p$ aryl, $S(O)_p$ heterocyclyl, amino, alkoxy, alkylthio, arylthio, perhaloalkyl, aryl, aryloxy, arylalkyl, arylalkyloxy, heterocyclyl and heterocyclyl-alkyl;


p is 0, 1 or 2;

X^3 for each occurrence is independently H or an optionally substituted moiety selected from the group consisting of mono- or di-alkylamino, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl and heterocyclyl-alkyl;

or when R^1 is in the 7-position of the benzothiazole ring, R^1 and W can be taken together with the carbon atoms to which they are attached to form an optionally substituted 5- or 6-membered heterocyclyl ring;

R^3 is hydrogen, or an optionally substituted moiety selected from the group consisting of carbonyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclyl-alkyl, heterocyclyl-heterocyclyl, heterocyclyl-cycloalkyl, amino, alkylamino, arylamino, alkoxy, thioalkoxy and acyl;

or R^3 and X^1 are taken together with the nitrogen atom to which they are attached to form



where Z for each occurrence is independently selected from the group consisting of oxo, or an optionally substituted moiety selected from the group consisting of $-C(O)(C_1-C_6)alkyl$, $-C(O)aryl$, $-C(O)N(C_1-C_6)alkyl$, $-C(O)N-aryl$, $(C_1-C_6)alkyl$, $(C_2-C_6)alkenyl$, $(C_2-C_6)alkynyl$, amino, mono- or di- $(C_1-C_6)alkylamino$, $-COO(C_1-C_6)alkyl$, pyridyl, phenyl, phenyl $(C_1-C_6)alkyl$ and phenyl $(C_1-C_6)alkenyl$;

where each of the optionally substituted moieties described hereinabove is optionally substituted by one or more substituents each independently selected from the group consisting of oxo, amino, nitro, mono- or bi-(C₁-C₆)alkylamino, hydroxy, nitrile, chloro, fluoro, bromo, iodo, CF₃, (C₁-C₆)alkyl, -C(O)(C₁-C₆)alkyl, -COOH, -COO(C₁-C₆)alkyl, -S-(C₁-C₆)alkyl, -S-aryl, (C₁-C₆)alkoxy, -SO₂NH₂, phenyl, phenyl(C₁-C₆)alkyl, -O-(C₁-C₆)alkyl-OH, -O-(C₁-C₆)alkyl-O-(C₁-C₆)alkyl, -O-(C₂-C₆)alkyl-N-((C₁-C₆)alkyl)_n, -N-(C₁-C₆)alkyl-OH, -N-(C₁-C₆)alkyl-O-(C₁-C₆)alkyl, -C(O)NH₂, -C(O)N((C₁-C₆)alkyl)_n, -S(O)_n(C₁-C₆)alkyl, -S(O)_naryl, -S(O)_nheterocyclyl, and heterocyclyl, where the alkyl groups mentioned herein optionally have one or more unsaturated bonds in the alkyl portion;

n is 0, 1 or 2,

in conjunction with glucocorticosteroid therapy in a patient undergoing glucocorticosteroid therapy comprising the step of replacing a portion of the amount of glucocorticosteroid administered to said patient and systemically administering the glucocorticosteroid and compound of formula (IB) or a pharmaceutically acceptable salt thereof.

Applicants noticed that the Office Action mailed October 17, 2002 was mailed to Lahive & Cockfield, the prior correspondence address. Applicants respectfully point out that a Change of Correspondence Address was filed on August 23, 2002 and request that the Examiner mail future correspondence to the address listed in said Change of Correspondence Address.

Applicants also observe that the Office Action mailed October 17, 2002 listed the First Named Inventor as Kevin P. Cusack. Applicants respectfully point out that a Request to Change the Order of Inventors was filed on August 23, 2002, requesting that the inventors be listed in the following order: Barbara Scott, Lee D. Arnold, Anna M. Ericsson and Kevin P. Cusack. Applicants respectfully request that the Order of Inventors be changed as previously requested and that this application be referred to with Barbara Scott as the First Named Inventor.

REMARKS

Reconsideration of the Office Action mailed October 17, 2002, (hereinafter "instant Office Action"), entry of the foregoing amendments and withdrawal of the rejection of claims 58-60, are respectfully requested.

In the instant Office Action, claims 1-60 are listed as pending, claim 1-57 are listed as withdrawn from consideration and claims 58-60 are listed as rejected.

Attached hereto as Appendix A is a marked-up version of the changes made to the claims by the current amendments. Appendix A is captioned "Version with markings to show changes made".

In reply to the Restriction Requirement, Applicants provisionally elected the species N-ethyl-N'-(6-nitro-1,3-benzothiazol-2-yl)urea which is Example 8 on page 70 of the instant specification with traverse. In the instant Office Action, the Examiner has withdrawn Claims 1-57 from consideration, stating that the first proviso in claim 1 excludes the elected invention.

The Examiner has rejected claims 59 and 60 under 35 U.S.C. §112, second paragraph, for allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner alleges that the claims do not recite steps toward the administration of the compound. Claims 59 and 60 have been amended to additionally recite the step of systemically administering the compound. Support for these